<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218722</url>
  </required_header>
  <id_info>
    <org_study_id>38RC16.046</org_study_id>
    <nct_id>NCT03218722</nct_id>
  </id_info>
  <brief_title>Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma</brief_title>
  <acronym>PROCOAG</acronym>
  <official_title>Impact of Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute traumatic coagulopathy (ATC) is common in severe trauma patients (around 25 to 30% of&#xD;
      patients with severe trauma) and is associated with increased mortality. ATC is associated&#xD;
      with fibrinogen and clotting factors deficiencies. Therefore, ATC management relies on early&#xD;
      administration of fibrinogen and blood products in case of massive transfusion with a 1:1 or&#xD;
      1:2 ratio between Fresh Frozen Plasma (FFP) and Red Blood Cells (RBC). This strategy relies&#xD;
      on fast supply of FFP.&#xD;
&#xD;
      To overcome delay for FFP ordering, transport and defrosting, the PROCOAG study proposes to&#xD;
      use prothrombrin concentrate complex (PCC) as alternative to treat coagulation factor&#xD;
      deficiency. PCC is readily available upon hospital arrival. In addition to fibrinogen&#xD;
      treatment, it is thought that PCC can be efficient in ATC management, while reducing risks&#xD;
      associated with massive transfusion.&#xD;
&#xD;
      ProCoag is a randomized, controlled, double-blinded, parallel clinical trial aiming at&#xD;
      showing superiority of early PPC+ fibrinogen strategy on fibrinogen only strategy for the&#xD;
      management of patients at risk of massive transfusion.&#xD;
&#xD;
      Early administration of PPC should optimize patient blood management and therefore reduce&#xD;
      blood products transfused within the first 24 hours following a severe trauma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Labile blood products transfused in the first 24 hours</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>This outcome is measured in number of bags administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RBC (Red Blood Cells) transfused in the first 24 hours</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>This outcome is measured in number of bags administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFP transfused in the first 24 hours</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>This outcome is measured in number of bags administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets transfused in the first 24 hours</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>This outcome is measured in number of bags administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve Prothrombin ratio &lt; 1.5</measure>
    <time_frame>Within the first 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hemostasis</measure>
    <time_frame>Within the first 24 hours following admission</time_frame>
    <description>Hemostasis is defined as bleeding control in the surgical field or resolution of contrast blush after embolization during interventional radiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombo-embolic events</measure>
    <time_frame>ICU stay (an average of 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 hours and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days</measure>
    <time_frame>Hospital stay (an average of 28 days)</time_frame>
    <description>Number of in-hospital days outside Intensive Care Unit (ICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-Free Days</measure>
    <time_frame>ICU stay (an average of 21 days)</time_frame>
    <description>Number of days without mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days</measure>
    <time_frame>Within the first 28 days</time_frame>
    <description>Number of days outside hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome Scale Extended (GOSE)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation status</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of the strategy</measure>
    <time_frame>Day 8 and Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Shock, Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>PCC treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Conventional strategy for ATC management without PCC (NaCl 0.9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pro-Thrombin Concentrate Complex</intervention_name>
    <description>Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.</description>
    <arm_group_label>PCC treatment</arm_group_label>
    <other_name>KANOKAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.</description>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Primary admission for a severe trauma&#xD;
&#xD;
          -  Out-of-hospital transfusion or RBC transfusion within the first hour following&#xD;
             hospital admission&#xD;
&#xD;
          -  Clinical prediction or ABC score (Assessment of Blood Consumption) ≥ 2 of massive&#xD;
             transfusion defined by a transfusion of at least 10 CGR during the first 24 hours or 3&#xD;
             CGR during the first hour.&#xD;
&#xD;
          -  Informed consent signed by a relative or emergency procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac arrest before randomisation&#xD;
&#xD;
          -  Secondary transfer from another hospital (a technical stop is accepted)&#xD;
&#xD;
          -  Post-traumatic lesions out of therapeutic resources with death expected in the hour&#xD;
             following hospital admission&#xD;
&#xD;
          -  Anti-coagulation treatment (K anti-vitamine, new oral anticoagulant)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hypersensitivity to active substances or one of the excipients of KANOKAD®&#xD;
&#xD;
          -  Patient treated with an experimental medicine within the last 30 days&#xD;
&#xD;
          -  Decision of therapeutic limitation before randomisation&#xD;
&#xD;
          -  Patient protected by article L1121-7 of the French Public health code.&#xD;
&#xD;
          -  Knowledge of a contraindication to the use of NaCl 0.9% at the dose of 1 mg/kg&#xD;
             (hyperchloremia, hypernatremia...)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre BOUZAT</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble Alpes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Annecy University Hospital</name>
      <address>
        <city>Annecy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM - Marseille Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44 093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL - Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute traumatic coagulopathy</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Severe hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Shock, Hemorrhagic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

